TABLE OF CONTENTS
1 Executive Summary
1.1 MARKET SYNOPSIS 22
1.2 MARKET ATTRACTIVENESS ANALYSIS 23
1.3 GLOBAL URINALYSIS TEST MARKET, BY PRODUCT TYPE 24
1.4 GLOBAL URINALYSIS TEST MARKET, BY TEST TYPE 25
1.5 GLOBAL URINALYSIS TEST MARKET, BY APPLICATION 26
1.6 GLOBAL URINALYSIS TEST MARKET, BY END USER 27
2 Market Introduction
2.1 DEFINITION 28
2.2 SCOPE OF THE STUDY 28
2.3 RESEARCH OBJECTIVE 28
2.4 MARKET STRUCTURE 28
2.5 ASSUMPTIONS & LIMITATIONS 29
3 Research Methodology
3.1 DATA MINING 30
3.2 SECONDARY RESEARCH 31
3.3 PRIMARY RESEARCH 32
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 33
3.5 FORECASTING TECHNIQUES 34
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 35
3.6.1 BOTTOM-UP APPROACH 36
3.6.2 TOP-DOWN APPROACH 36
3.7 DATA TRIANGULATION 37
3.8 VALIDATION 37
4 MARKET DYNAMICS
4.1 OVERVIEW 38
4.2 DRIVERS 39
4.2.1 RISING PREVALENCE OF DIABETES 39
4.2.2 RISING PREVALENCE OF KIDNEY DISEASES 39
4.2.3 GROWING NUMBER OF RESEARCH ORGANIZATIONS AND ASSOCIATIONS FOR DIABETES 39
4.2.4 INCREASING GERIATRIC POPULATION AND THE INFLUENCE OF SEDENTARY LIFESTYLE AND UNHEALTHY DIET 40
4.3 RESTRAINTS 41
4.3.1 STRINGENT REIMBURSEMENT POLICIES IN DEVELOPING COUNTRIES 41
4.3.2 SUPPLY OF DEFECTIVE AND FAULTY PRODUCTS 41
4.4 OPPORTUNITIES 42
4.4.1 INCREASING APPROVALS AND PRODUCT LAUNCHES 42
4.4.2 EXPANSION IN DEVELOPING ECONOMIES 42
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL 43
5.1.1 THREAT OF NEW ENTRANTS 43
5.1.2 BARGAINING POWER OF SUPPLIERS 44
5.1.3 THREAT OF SUBSTITUTES 44
5.1.4 BARGAINING POWER OF BUYERS 44
5.1.5 INTENSITY OF RIVALRY 44
5.2 VALUE CHAIN ANALYSIS 45
5.2.1 R&D AND DESIGNING 45
5.2.2 MANUFACTURING 45
5.2.3 DISTRIBUTION 46
5.2.4 MARKETING & SALES 46
5.2.5 POST-SALES MONITORING 46
6 GLOBAL URINALYSIS TEST MARKET, BY PRODUCT TYPE
6.1 OVERVIEW 47
6.2 CONSUMABLES 48
6.2.1 PREGNANCY & FERTILITY KITSC 49
6.2.2 DIPSTICKS 50
6.2.3 DISPOSABLES REAGENTS 50
6.2.4 REAGENTS 51
6.3 INSTRUMENTS 51
6.3.1 AUTOMATED URINE ANALYZERS 52
6.3.2 SEMI-AUTOMATED URINE ANALYZERS 56
6.3.3 POINT-OF-CARE URINE ANALYZERS 57
7 GLOBAL URINALYSIS TEST MARKET, TEST TYPE
7.1 OVERVIEW 58
7.2 SEDIMENT ANALYSIS 59
7.3 BIOCHEMICAL ANALYSIS 60
7.3.1 LABORATORY TESTS 61
7.3.2 POINT-OF-CARE TESTS 61
7.4 PREGNANCY AND FERTILITY TESTS 62
8 GLOBAL URINALYSIS TEST MARKET, APPLICATION
8.1 OVERVIEW 63
8.2 DISEASE DIAGNOSIS 64
8.2.1 KIDNEY DISEASES 65
8.2.2 DIABETES 66
8.2.3 URINARY TRACT INFECTIONS 67
8.3 PREGNANCY & FERTILITY 68
9 GLOBAL URINALYSIS TEST MARKET, END USER
9.1 OVERVIEW 69
9.2 HOSPITALS AND CLINICS 70
9.3 DIAGNOSTIC LABORATORIES 71
9.4 HOME CARE SETTINGS 72
9.5 OTHERS 72
10 GLOBAL URINALYSIS TEST MARKET, BY REGION
10.1 OVERVIEW 73
10.2 AMERICAS 75
10.2.1 NORTH AMERICA 80
10.2.2 LATIN AMERICA 93
10.3 EUROPE 98
10.3.1 WESTERN EUROPE 103
10.3.2 EASTERN EUROPE 134
10.4 ASIA-PACIFIC 139
10.4.1 CHINA 144
10.4.2 JAPAN 148
10.4.3 INDIA 152
10.4.4 AUSTRALIA 157
10.4.5 SOUTH KOREA 161
10.4.6 REST OF ASIA-PACIFIC 165
10.5 MIDDLE EAST & AFRICA 170
10.5.1 MIDDLE EAST 175
10.5.2 AFRICA 179
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 183
11.2 COMPETITIVE BENCHMARKING 184
11.3 GLOBAL URINALYSIS TEST MARKET, COMPANY SHARE ANALYSIS, 2018 186
11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL URINALYSIS TEST MARKET 186
11.5 KEY DEVELOPMENT ANALYSIS 187
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 187
11.6.1 CONTRACTS & AGREEMENTS 187
11.6.2 MERGER & ACQUISITION 188
11.6.3 NEW PRODUCT LAUNCH 188
11.6.4 EXPANSIONS 188
11.6.5 APPROVALS 189
12 COMPANY PROFILES
12.1 ABBOTT LABORATORIES 190
12.1.1 COMPANY OVERVIEW 190
12.1.2 FINANCIAL OVERVIEW 190
12.1.3 PRODUCTS/SERVICES OFFERED 191
12.1.4 ABBOTT LABORATORIES: KEY DEVELOPMENTS 191
12.1.5 SWOT ANALYSIS 191
12.1.6 KEY STRATEGIES 191
12.2 BIO-RAD LABORATORIES, INC. 192
12.2.1 COMPANY OVERVIEW 192
12.2.2 FINANCIAL OVERVIEW 192
12.2.3 PRODUCTS/SERVICES OFFERED 193
12.2.4 KEY DEVELOPMENTS 193
12.2.5 SWOT ANALYSIS 193
12.2.6 KEY STRATEGIES 194
12.3 BECKMAN COULTER INC. 195
12.3.1 COMPANY OVERVIEW 195
12.3.2 FINANCIAL OVERVIEW 195
12.3.3 PRODUCTS/SERVICES OFFERED 196
12.3.4 KEY DEVELOPMENTS 196
12.3.5 SWOT ANALYSIS 196
12.3.6 KEY STRATEGIES 197
12.4 F. HOFFMANN-LA ROCHE LTD 198
12.4.1 COMPANY OVERVIEW 198
12.4.2 FINANCIAL OVERVIEW 198
12.4.3 PRODUCTS/SERVICES OFFERED 199
12.4.4 KEY DEVELOPMENTS 199
12.4.5 SWOT ANALYSIS 199
12.4.6 KEY STRATEGIES 199
12.5 SIEMENS HEALTHINEERS 200
12.5.1 COMPANY OVERVIEW 200
12.5.2 FINANCIAL OVERVIEW 200
12.5.3 PRODUCTS/SERVICES OFFERED 201
12.5.4 KEY DEVELOPMENTS 201
12.5.5 SWOT ANALYSIS 202
12.5.6 KEY STRATEGIES 202
12.6 EKF DIAGNOSTICS 203
12.6.1 COMPANY OVERVIEW 203
12.6.2 FINANCIAL OVERVIEW 203
12.6.3 PRODUCTS/SERVICES OFFERED 204
12.6.4 KEY DEVELOPMENTS 204
12.6.5 SWOT ANALYSIS 204
12.6.6 KEY STRATEGIES 205
12.7 ARKRAY, INC. 206
12.7.1 COMPANY OVERVIEW 206
12.7.2 ARKRAY, INC.: FINANCIAL OVERVIEW 206
12.7.3 PRODUCTS/SERVICES OFFERED 206
12.7.4 KEY DEVELOPMENTS 206
12.7.5 SWOT ANALYSIS 207
12.7.6 KEY STRATEGIES 207
12.8 TRINITY BIOTECH PLC 208
12.8.1 COMPANY OVERVIEW 208
12.8.2 FINANCIAL OVERVIEW 208
12.8.3 PRODUCTS/SERVICES OFFERED 209
12.8.4 KEY DEVELOPMENTS 209
12.8.5 SWOT ANALYSIS 209
12.8.6 KEY STRATEGIES 209
12.9 ANALYTICON BIOTECHNOLOGIES AG 210
12.9.1 COMPANY OVERVIEW 210
12.9.2 FINANCIAL OVERVIEW 210
12.9.3 PRODUCTS/SERVICES OFFERED 210
12.9.4 KEY DEVELOPMENTS 210
12.9.5 SWOT ANALYSIS 211
12.9.6 KEY STRATEGIES 211
12.10 77 ELEKTRONIKA KFT. 212
12.10.1 COMPANY OVERVIEW 212
12.10.2 FINANCIAL OVERVIEW 212
12.10.3 PRODUCTS/SERVICES OFFERED 212
12.10.4 KEY DEVELOPMENTS 212
12.10.5 SWOT ANALYS 213
12.10.6 KEY STRATEGIES 213
12.11 YD DIAGNOSTICS 214
12.11.1 COMPANY OVERVIEW 214
12.11.2 FINANCIAL OVERVIEW 214
12.11.3 PRODUCTS/SERVICES OFFERED 214
12.11.4 KEY DEVELOPMENTS 214
12.11.5 SWOT ANALYSIS 215
12.11.6 KEY STRATEGIES 215
12.12 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD 216
12.12.1 COMPANY OVERVIEW 216
12.12.2 FINANCIAL OVERVIEW 216
12.12.3 PRODUCTS/SERVICES OFFERED 216
12.12.4 KEY DEVELOPMENTS 216
12.12.5 SWOT ANALYS 217
12.12.6 KEY STRATEGIES 217
12.13 ERBA MANNHEIM 218
12.13.1 COMPANY OVERVIEW 218
12.13.2 FINANCIAL OVERVIEW 218
12.13.3 PRODUCTS/SERVICES OFFERED 218
12.13.4 KEY DEVELOPMENTS 218
12.13.5 SWOT ANALYS 219
12.13.6 KEY STRATEGIES 219
12.14 CARDINAL HEALTH 220
12.14.1 COMPANY OVERVIEW 220
12.14.2 FINANCIAL OVERVIEW 220
12.14.3 PRODUCTS/SERVICES OFFERED 221
12.14.4 KEY DEVELOPMENTS 221
12.14.5 SWOT ANALYSIS 221
12.14.6 KEY STRATEGY 221
12.15 THERMO FISHER SCIENTIFIC INC. 222
12.15.1 COMPANY OVERVIEW 222
12.15.2 FINANCIAL OVERVIEW 222
12.15.3 PRODUCTS/SERVICES OFFERED 223
12.15.4 KEY DEVELOPMENTS 223
12.15.5 SWOT ANALYSIS 223
12.15.6 KEY STRATEGIES 223
12.16 QUIDEL CORPORATION 224
12.16.1 COMPANY OVERVIEW 224
12.16.2 FINANCIAL OVERVIEW 224
12.16.3 PRODUCTS/SERVICES OFFERED 225
12.16.4 KEY DEVELOPMENTS 225
12.16.5 SWOT ANALYSIS 225
12.16.6 KEY STRATEGIES 225
12.17 SYSMEX CORPORATION 226
12.17.1 COMPANY OVERVIEW 226
12.17.2 FINANCIAL OVERVIEW 226
12.17.3 PRODUCTS/SERVICES OFFERED 227
12.17.4 KEY DEVELOPMENTS 227
12.17.5 SWOT ANALYS 227
12.17.6 KEY STRATEGIES 228
12.18 ACON LABORATORIES, INC. 229
12.18.1 COMPANY OVERVIEW 229
12.18.2 FINANCIAL OVERVIEW 229
12.18.3 PRODUCTS/SERVICES OFFERED 229
12.18.4 KEY DEVELOPMENTS 229
12.18.5 SWOT ANALYSIS 230
12.18.6 KEY STRATEGIES 230
12.19 BECTON, DICKINSON AND COMPANY 231
12.19.1 COMPANY OVERVIEW 231
12.19.2 FINANCIAL OVERVIEW 231
12.19.3 PRODUCTS/SERVICES OFFERED 232
12.19.4 KEY DEVELOPMENTS 232
12.19.5 SWOT ANALYS 232
12.19.6 KEY STRATEGIES 232
12.20 URIT MEDICAL ELECTRONIC C0., LTD 233
12.20.1 COMPANY OVERVIEW 233
12.20.2 FINANCIAL OVERVIEW 233
12.20.3 PRODUCTS/SERVICES OFFERED 233
12.20.4 KEY DEVELOPMENTS 233
12.20.5 SWOT ANALYSIS 234
12.20.6 KEY STRATEGIES 234
12.21 DIRUI 235
12.21.1 COMPANY OVERVIEW 235
12.21.2 FINANCIAL OVERVIEW 235
12.21.3 PRODUCTS/SERVICES OFFERED 235
12.21.4 KEY DEVELOPMENTS 235
12.21.5 SWOT ANALYS 236
12.21.6 KEY STRATEGIES 236
13 APPENDIX
13.1 REFERENCES 237
13.2 RELATED REPORTS 237
